Renal vasodilation produced by two dissimilar vasodepressor polypeptides, bradykinin and eledoisin, was correlated with changes in renal venous concentrations of substances having the properties of prostaglandins of the E and F series in anesthetized dogs. Samples of renal venous blood were extracted for acidic lipids, and the prostaglandin E and prostaglandin F zones of the chromatographed extracts were eluted and assayed in vitro for prostaglandins of the E and F series by a parallel bioassay system (sensitivity 0.015 ng/ml blood). During the first 2 minutes of infusion, bradykinin increased the concentration of a prostaglandin E-like substance in renal venous blood from a mean control level of 0.16 ng/ml to 1.05 ng/ml (P <0.01); this increase occurred simultaneously with the greatest increase in renal blood flow to 432 ml/min from a control value of 282 ml/min. After 12 minutes of bradyldnin infusion, the concentration of the prostaglandin E-like substance had decreased to 0.30 ng/ml, and renal blood flow had fallen to 398 ml/min. In contrast, eledoisin infused in equidilator doses did not increase the concentration of the prostaglandin E-like substance. The concentration of prostaglandin F-like substances was not affected by either polypepride. A transient increase in urine flow occurred during the first 2 minutes of bradykinin infusion only. These results suggest that a prostaglandin E-like substance participates in the renal vasodilator and the diuretic responses to bradykinin. • Vasodilator substances differ not only in their capacity to increase blood flow to an organ but also in their effects on vascular elements within an organ. Thus, the threshold dose of bradykinin which increases renal blood flow is similar to that dose which increases femoral blood flow (1). In contrast, the threshold dose of isoproterenol which increases femoral blood flow is without effect on renal blood flow (1). Furthermore, bradykinin constricts veins (2), but isoproterenol usually dilates them (3). For the renal circulation, vasodilator agents may be further distinguished by their differential effects on the regional redistribution of blood flow within the kidney (4). In this paper we describe an additional differential action of vasodilator agents: their effect on release of prostaglandins from the canine kidney is examined. It has been proposed that prostaglandins function in an intrarenal regulatory system (5). We related the renal activity of two chemically unrelated vasodilator polypeptides, the nonapeptide bradykinin and the endecapeptide eledoisin, to changes in the 
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Received November 8, 1971 . Accepted for publication April 24, 1972. increases femoral blood flow is without effect on renal blood flow (1) . Furthermore, bradykinin constricts veins (2) , but isoproterenol usually dilates them (3) . For the renal circulation, vasodilator agents may be further distinguished by their differential effects on the regional redistribution of blood flow within the kidney (4) . In this paper we describe an additional differential action of vasodilator agents: their effect on release of prostaglandins from the canine kidney is examined. It has been proposed that prostaglandins function in an intrarenal regulatory system (5) . We related the renal activity of two chemically unrelated vasodilator polypeptides, the nonapeptide bradykinin and the endecapeptide eledoisin, to changes in the concentration of prostaglandins of the E (PGE) and F (PGF) series in renal venous blood. Bradykinin increased renal blood flow and urine flow; these changes coincided with an increase in the concentration in renal venous blood of a substance which was indistinguishable from a prostaglandin of the E series (PGE-like) by physicochemical and biological criteria. In contrast, equidilator doses of eledoisin did not affect the concentrations of prostaglandins of either the E or the F series in renal venous blood.
Methods
Eight mongrel dogs, weighing 22-31 kg, were fasted for 12 hours prior to the experiment but allowed free access to water. They were anesthetized with morphine sulfate (2 mg/kg, sc) and chloralose (100 mg/kg, iv). To maintain anesthesia, chloralose (40 mg/kg, iv) was given every 3-4 hours. The trachea was cannulated, and the lungs were ventilated mechanically. The renal arteries, the ureters, and the right renal vein were isolated through a transabdominal incision. Two eight-channel direct writers (Hewlett-Packard, models 7720 and 7718) recorded: (1) mean aortic blood pressure measured by a Statham transducer (model P23Db) via a catheter inserted in a retrograde direction into a femoral artery, (2) renal blood flow measured by electromagnetic flowmeters (Statham, model M-4001), (3) urine drops counted by a Grass photoelectric transducer (PTTI), and (4) changes in length of assay organs measured by isotonic transducers (Harvard Apparatus, model 358).
In six experiments, bradykinin (20-100 ng kg-1 min-1 ) and eledoisin (37.5-150 ng kg" 1 mh-r 1 ) were infused alternately into the renal artery for 20 minutes at a rate which increased renal blood flow by at least 30% without affecting aortic blood pressure. The rate of infusion of eledoisin was limited by its hypotensive effect, which attenuated or abolished its renal vasodilator action. Hypotension occurred invariably when the rate of administration of eledoisin exceeded 150 ng kg-1 min"
1 . Unlike bradykinin, eledoisin is neither inactivated in blood nor removed by the lungs (6) . Changes in renal blood flow and in concentrations of PGE-or PGF-like substances in renal venous blood were unaffected by the sequence of administration of the polypeptides. Intervals of 30 minutes were allowed between infusions of either polypeptide. In two additional experiments, only bradykinin was infused. Bradykinin and eledoisin were infused into the renal artery by a Braun continuous-infusion apparatus Circulation Ktsurcb, Vol. XXXI, July 1972 (model Unita 1) in appropriate concentrations so that the rate did not exceed 1 ml/min. A sustaining infusion of 0.9% saline was administered intravenously at a rate of 4-6 ml/min. Heparin (1500 IU/kg, iv) was given just prior to supervising (streaming of fluid over the assay organs) the assay tissues with blood. In five of the eight experiments, rates of excretion of sodium from the experimental kidney were determined for three periods before and two periods, 10 minutes in duration each, during infusion of bradykinin into the renal artery. Urinary sodium concentration was determined by flame photometry.
In nine and six additional experiments PGE., (4 ng kg-1 min-1 ) and PGF 2O (40 ng kg" 1 min" 1 ), respectively, were infused into the renal artery for 5-10 minutes-, and their effects on renal blood flow and urine flow were related to the concentration of either prostaglandin in renal arterial blood. We had determined in preliminary experiments that PGF 2a infused at the same rate as PGE 2 was without effect on renal blood flow.
We have reported the adaptation of the bloodbathed organ technique of Vane (7) to the continuous assay of renal venous effluent (8) . In brief, three assay organs, rat stomach strip, rat colon, and chick rectum, were superfused in series by renal venous blood withdrawn by a pump at 15 ml/min and returned to the dog via the left jugular vein. The in vivo assay system, in addition to continuously assaying changes in the concentration of prostaglandinlike substances in renal venous blood, was used to determine the optimal time for collection of renal venous blood. These samples of blood were then assayed for concentrations of PGE-and PGF-like substances by the same assay organs in vitro after the acidic lipids had been extracted and the extracts chromatographed.
For example, the first collection of blood during bradykinin infusion was prompted by the initial large contraction of the assay organs coincident with the peak increase in renal blood flow (Fig.  1) . The unsustained contraction of the assay organs during bradykinin infusion suggested a waning of the concentration of prostaglandinlike substances in renal venous blood. These estimates of changes in concentrations of prostaglandins provided by continuous monitoring of renal venous blood in vivo were confirmed by the results of the in vitro assay: an initial severalfold increase in the concentration of a PGE-like substance was observed, but it was not sustained (Fig. 2) . Thus, based on the information provided by the in vivo assay system, venous blood (100 ml) was collected in etfianol before and during infusion of bradykinin into the renal 
FIGURE 1

Effects of bradykinin (BK), infused for 20 minutes into the renal artery (IRA), on urine flow, mean aortic blood pressure (BP), renal blood flow, and assay organs (rat stomach strip [RSS]; rat colon [RC], and chick rectum. [CR] superfused by venous blood of the same kidney in a chloralose-anesthetized dog. Every tenth drop is marked by the decade counter. Contraction of the assay organs produced hy infusion of bradykinin into the renal artery (lower left) was matched by a PCE t standard but not by bradykinin infused directly into the extracorporeal circuit (IBB), thereby bypassing the kidney (matching infusions, lower right). The times that renal venous blood was collected for assay are indicated by the black bars. Concentrations of PGE-and PGF-like substances in the purified extracts of renal venous blood were determined by bracket assay as shown (upper right) for an eluate of the PGF zone of the thin-layer plate. ThC = thin-layer chromatography.
artery, once within the first 2 minutes and then 12 minutes after the onset of infusion. Dextran (average molecular weight 75,000) was infused intravenously at the same rate at which renal venous blood was removed. The ethanol-blood mixture was filtered and evaporated, and the acidic lipids were separated from the neutral lipids as previously described (9) . The acidic lipids were further purified by thin-layer chromatography on silica gel layers, 0.5 mm in thickness, with a chloroform-methanol-acetic acid solvent system (18:1:1 by volume). Eluates-from thinlayer chromatographic zones were reconstituted in Krebs solution to a final volume of 0.5 ml; 0.1-ml samples of the latter were assayed in vitro for prostaglandins. The threshold of sensitivity of this assay system for PGE-like substances expressed as PGE 2 equivalents was 0.015 ng/ml blood or less, since we could always detect as little as 1.5 ng in the reconstituted eluate, which represented the purified extract of 100 ml of blood. Thus, the sensitivity of this assay for PGE 2 is well below the tjireshold value of 0.1 ng/ml blood for PGE 2 -induced increases of renal blood flow (10) . The concentrations of PGE-and PGF-like substances in eluates were determined by bracket assay (Figs. 1, 3 ) and by relating their effects on the recorded lengths of assay organs to the doseresponse curve obtained for PGE 2 or PGF 2ct standards on the most sensitive assay organ, usually the rat stomach. Since preliminary purification eliminated interfering substances, only two assay organs were usually used for in vitro assays, but in one-third of the assays all three tissues were used. The precision of this assay procedure, expressed as the coefficient of variation, was 9.2%. Concentrations of prostaglandins were not corrected for losses (average 62/6) incurred on extraction and purification (9) . PGE 2 and PGF 2a were crystalline samples and were prepared as 1-mg/ml stock solutions in 95% ethanol and diluted before use with 0.9K saline. Synthetic bradykinin (batch 01312, Sandoz Pharmaceuticals) and synthetic eledoisin (batch 63005, Sandoz Pharmaceuticals) were prepared in 0.9% saline on the day of the experiment. Potencies of the polypeptides and the prostaglandins were tested for uniformity by comparing their relative activities on either the assay organs or renal blood flow. We did not observe Changes in renal blood flow and in the concentrations of PGE-and PGF-like substances were tested for statistical significance by the ttest based on paired observations or by the sign test. A P value of 0.05 or less was considered statistically significant. Statistical analyses were performed according to methods described by Steel and Torrie (11) .
Results
EFFECTS OF BRADYKININ
Bradykinin increased mean renal blood flow initially by 150 ml/min from a control value of 282 ml/min (P<0.01) without affecting aortic blood pressure (Fig. 2) . The concentration of a PGE-like substance was invariably increased severalfold from a control value of 0.16±0.04 (SE) ng/ml 2 minutes after GrcuUHo* Resemrcb, Vol. XXXI, July 1972 starting the infusion of bradykinin. The mean increase was 0.89 ± 0.16 ng/ml and the range was 0.25 ng/ml to 1.02 ng/ml (P<0.01) (Fig. 2) . During bradykinin infusion, the peak concentrations of PGE-and PGF-like substances in renal venous effluent at 2 minutes corresponded in time to the greatest increase in renal blood flow and the maximal activity of the assay tissues superfused directly with renal venous blood. Thus, in Figure 1 , the bradyldnin-induced increase in renal blood flow of 193 ml/min at 2 minutes coincided with the peak contraction of the assay tissues superfused with renal venous blood. Twelve minutes after starting the bradykinin infusion, renal blood flow had fallen from its highest value of 523 ml/min to 482 ml/min, and the assay tissues had returned to their control state. These changes in the activity of the assay tissues in vivo produced by bradykinin corresponded to the concentration of a PGElike substance in renal venous blood determined on samples obtained during infusion of bradykinin: an elevenfold increase above control at 2 minutes fell to levels less than twofold above the control value at 12 minutes. During the first 1-2 minutes of bradykinin infusion, a transient increase in urine flow occurred simultaneously with the phase of the most rapid increase in renal blood flow (Fig.  3) . However, this initial transient increase in urine flow in response to bradykinin was not reflected by changes in either urine volume or sodium excretion determined before and during infusion of bradykinin. Thus, the mean control values for urine volume and sodium excretion for the experimental kidney were 0.27 ml/min and 19 /iEq/min, respectively, and the corresponding values for the same kidney during infusion of bradykinin were 0.29 ml/min and 23 /*Eq/min (P>0.1 for changes in urine volume and sodium excretion). Bradykinin has been reported to produce a sustained diuresis (12) . Failure to do so under these experimental conditions is presumably related, in part, to the anesthetic agent, chloralose, since changes in urine flow and sodium excretion in response to bradykinin were reported to be variable in dogs anesthetized with chloralose (13) .
Renal blood flow 12 minutes after starting bradykinin infusion had decreased to a mean value of 398 ml/min from the peak value of 432 ml/min, and the simultaneously determined renal venous concentration of the PGElike substance had decreased to a mean of 0.30 ±0.06 ng/ml (Fig. 2) . The latter, although significantly less (P < 0.01) than the mean concentration of 1.05 ng/ml determined at the time of the peak value of renal blood flow, was significantly greater than the control level of 0.16 ng/ml (P<0.05). The concentration of a PGF-like substance in renal venous blood did not change significantly during bradykinin infusion. Within 7 minutes after stopping bradykinin infusion, mean renal blood flow returned to 274 ml/min; this value was not significantly different from the control renal blood flow. In five experiments the concentrations of PGE-and PGF-like substances determined within 30 minutes after stopping bradykinin infusion were similar to control values; for the PGE-like substances control and recovery values were 0.18 ± 0.05 ng/ml and 0.15 ±0.07 ng/ml, respectively, and for the PGF-like substances the corresponding values were 0.06 ± 0.03 ng/ml and 0.1 ± 0.04 ng/ml.
EFFECTS OF ELEDOISIN
Eledoisin increased mean renal blood flow to 404 ml/min from a control value of 297 ml/min (P < 0.01) without significantly affecting systemic blood pressure. However, the range of this increase in renal blood flow was 48 ml/min to 193 ml/min. Eledoisin, unlike bradykinin, produced neither an initial peak in renal blood flow nor an increase in urine flow during the first 2 minutes of its infusion. Concentrations of either a PGE-or a PGF-like substance in renal venous blood did not change during infusion of eledoisin (Fig.  2) . Renal blood flow returned to control levels within 5 minutes after stopping eledoisin infusion.
EFFECTS OF PGE. A N D PGFto
In nine experiments PGE 2 infused into the renal artery at a rate of 4 ng kg" 1 mirr 1 , resulting in concentrations in renal arterial blood ranging from 0.21 ng/ml to 1.06 ng/ml (mean 0.53 ng/ml), increased renal blood flow by 35$ of control and urine drops by twoto threefold and did not affect systemic blood pressure (Table 1) . PGF 2O infused into the renal artery at a rate of 40 ng kg" 1 min" 1 , resulting in concentrations in renal arterial blood as high as 10 ng/ml, did not affect renal blood flow, urine flow, or mean aortic blood pressure.
Discussion
Increased concentration of a PGE-like substance in renal venous blood in response to CitcuUtion Rtiurcb, Vol. XXXI, J*ij 1972 The values are means = * = SE; for renal blood flow and urine flow they refer to the experimental kidney only. MABP = mean aortic blood pressure; RBF = renal blood flow; UF = urine flow. Statistical analyses were made using the paired (-test for experimental (prostaglandin) and control periods, NS indicates no statistically significant difference.
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bradykinin suggests participation of a renal prostaglandin in the renal vasodilator and diuretic actions of the kinin. These data, however, cannot be interpreted to support the view that the renal vasodilator activity of bradykinin is entirely, or even primarily, dependent on a mediator. The concentration of a PGE-like substance after 20 minutes of bradykinin infusion, although above control, was two-thirds less than the concentration occurring initially in response to bradykinin (Fig. 2) . However, the possibility that sustained release of a prostaglandin of the E series could account primarily for the renal vasodilator action of bradykinin cannot be dismissed, since rapid destruction of prostaglandins may occur close to their site of action after induction of catabolizing enzymes. This situation would be reflected by falling concentrations of the prostaglandins in renal venous blood in the face of only a moderate reduction of their activity intrarenally. Thus, concentrations of vasoactive substances in renal venous blood need not reflect their intrarenal activity, since the former is a resultant of rates of synthesis and degradation, receptor affinity, plasma-protein binding, and other factors which may change independently during infusion of bradykinin.
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However, before this proposal merits serious consideration, several questions should be considered. First, can changes in renal blood flow of the magnitude occurring in these experiments be mediated, even partially, by a substance which is synthesized or stored, or both, exclusively in the renal medulla? Second, are the activities of renal prostaglandins restricted to the renal medulla? The assumption on which these two questions are based-the exclusion of prostaglandins from the renal cortex in terms of activity, synthesis, or storage-challenges biochemical and histochemical evidence which assigns the major activity of the enzyme responsible for the degradation of prostaglandins, a 15-hydroxydehydrogenase, to the renal cortex (14, 15) . The activity of this enzyme in the kidney surpasses that in the lung, the site of the major biological inactivation of circulating prostaglandins (7). Pursuant to this finding, Anggard et al. (14) have urged a reconsideration of the evidence that the synthesis and site of activity of prostaglandins is restricted to the renal medulla. Third, is the identification of the substance appearing in renal venous blood dependent on relatively nonspecific methods? This question overlooks our procedures and criteria for characterization of the substance appearing in the venous effluent in response to bradykinin. Changes in the concentration of prostaglandinlike substances as determined by the in vivo assay system corresponded to those values obtained in vitro on samples subjected to preliminary extraction and biochemical purification. Extraction eliminated unwanted substances, primarily amines and polypeptides, which might have interfered with the detection of prostaglandins in the in vivo assay system. Thin-layer chromatography resulted in the exclusion of all acidic lipids except those having the mobility characteristics of prostaglandins of either the E or the F series, and the substances recovered from the E and F zones affected the assay tissues in the same way as did bradykinin in vivo. The application of this highly sensitive and specific bioassay system to the detection of prostaglandins in venous effluents has received abundant verification by Vane and his associates (7, 16) . Similarly, Horton (17) has observed that identification of prostaglandins on the basis of their biological effects and chromatographic behavior, although tentative, is highly suggestive. Inasmuch as we were dealing with small quantities of these substances, the use of procedures which depended on rigorous chemical identification was precluded.
We suggest that the PGE-like substance is probably PGE 2 , the major renal prostaglandin, since we have previously characterized the PGE-like substance released during renal ischemia as PGE 2 (8) . Furthermore, infusion of authentic PGE2, at a rate which produced concentrations in renal blood comparable to those of the PGE-like substance occurring in response to bradykinin, produced similar increments in renal blood flow (Table 1) (10, 18) . The failure of bradykinin to increase the concentration of a PGF-like substance is consistent with our proposal that the release of PGE 2 , a vasodilator, by bradykinin is related to the renovascular action of the kinin; PGF 2 a, which is present in the renal medulla in concentrations only slightly less than those of PGE 2 (19) , possesses pressor properties (20) and is without effect on renal blood flow (Table 1) . Heretofore, only ischemic or pressor stimuli have been shown to release renal prostaglandins (5, 8, 21) . The failure of another polypepride, eledoisin, given in equidilator doses to increase the concentration of either PGE-or PGF-like substances suggests the specificity of this relationship for bradykinin and challenges the hypothesis that prostaglandins subserve a general mechanism as local mediators of blood flow for vasoactive agents. Collier et al. (22, 23) have suggested that the vascular activity of bradykinin appears to be dependent, at least in part, on a mediator(s), since aspirin reduces the duration of the vasodepressor action of bradykinin. The recent demonstration by Ferreira et al. (16) that aspirin inhibits the synthesis of prostaglandins suggests that the putative mediator of the vasodepressor activity of bradykinin is a prostaglandin. Some of the seemingly paradoxical actions of bradykinin such as vasoconstriction in vitro and vasodilation and venoconstriction in vivo might be comprehensible, if they resulted from a mixture of direct effects and secondary effects related to release of an intermediary (24) . The latter is not without precedent, since bradykinin releases catecholamines and vasopressin (25, 26) . Although the renal vasodilator action may be partially mediated by a prostaglandin of the E series or a substance very similar to it, we cannot exclude a complementary or even antagonistic direct effect of bradykinin.
